2150-45-0

Basic information

• Product Name: METHYL 3,5-DIHYDROXYBENZOATE
• Synonyms: METHYL 2,6-DIHYDROXYBENZOATE;METHYL-A-RESORCYLATE;GAMMA-RESORCYLIC ACID METHYL ESTER;2,6-DIHYDROXYBENZOIC ACID METHYL ESTER;3,5-DIHYDROXYBENZOIC ACID METHYL ESTER;AKOS 227-38;ALPHA-RESORCYLIC ACID METHYL ESTER;RARECHEM AL BF 0252
• CAS NO: 2150-45-0
• Molecular Formula: C₈H₈O₄
• Molecular Weight: 168.15
• Product Categories: Aromatic Esters;Esters;Phenyls & Phenyl-Het;Phenyls & Phenyl-Het;C8 to C9;Carbonyl Compounds
• Mol File: 2150-45-0.mol
• Article Data: 29

Chemical Properties

• Melting Point: 67-70 °C(lit.)
• Boiling Point: 253.6°Cat760mmHg
• Flash Point: 101.1°C
• Appearance: /
• Density: 1.354g/cm³
• Vapor Pressure: 0.0113mmHg at 25°C
• Refractive Index: 1.587
• Storage Temp.: Inert atmosphere,Room Temperature
• Solubility: Acetone (Slightly), Methanol (Slightly)
• PKA: 9.24±0.10(Predicted)
• CAS DataBase Reference: METHYL 3,5-DIHYDROXYBENZOATE(CAS DataBase Reference)
• NIST Chemistry Reference: METHYL 3,5-DIHYDROXYBENZOATE(2150-45-0)
• EPA Substance Registry System: METHYL 3,5-DIHYDROXYBENZOATE(2150-45-0)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-37/39-36
• WGK Germany: 3
• Hazardous Substances Data: 2150-45-0(Hazardous Substances Data)

Usage

Description

METHYL 3,5-DIHYDROXYBENZOATE, also known as Methyl 2,6-dihydroxybenzoate, is an organic compound derived from 2,6-dihydroxybenzoic acid. It exhibits multiple fluorescence properties, with its short wavelength emission at 387 nm and long wavelength emission at 500 nm attributed to extramolecularly and intramolecularly hydrogen-bonded species, respectively.

Uses

Used in Chemical Synthesis:
METHYL 3,5-DIHYDROXYBENZOATE is used as a key intermediate in the synthesis of various compounds, such as methyl 2-hydroxy-6-methoxybenzoate and oxamyl propionic acid. Its unique chemical structure and properties make it a valuable building block for the development of new molecules with potential applications in different industries.
Used in Pharmaceutical Industry:
METHYL 3,5-DIHYDROXYBENZOATE can be utilized as a starting material for the development of new drugs or drug candidates. Its hydrogen-bonding capabilities and fluorescence properties may contribute to the design of novel therapeutic agents with improved efficacy and selectivity.
Used in Research and Development:
Due to its unique fluorescence properties, METHYL 3,5-DIHYDROXYBENZOATE can be employed in research and development for various applications, such as the study of molecular interactions, the development of new analytical methods, and the investigation of biological processes.
Used in Material Science:
The compound's fluorescence characteristics may also find applications in material science, where it could be used in the development of new materials with specific optical or electronic properties, such as sensors or optoelectronic devices.

InChI:InChI=1/C8H8O4/c1-12-8(11)7-5(9)3-2-4-6(7)10/h2-4,9-10H,1H3

Upstream product

• 67-56-1 methanol 
• 303-07-1 2,6-Dihydroxybenzoic acid 
• 186581-53-3 diazomethane 
• 79205-25-7 4-methylpyoluteorin O,O-diacetate 
• 124479-80-7 2‐(methoxycarbonyl)‐1,3‐phenylene diacetate 
• 74-88-4 methyl iodide 
• 25983-51-1 2,6-bis(benzyloxy)benzoic acid methyl ester 
• 1466-76-8 2-6-dimethoxybenzoic acid 
• 108-46-3 recorcinol 
• 77-78-1 dimethyl sulfate 

Downstream Products

• 90151-18-1 2,6-dihydroxy benzohydrazide 
• 3147-50-0 2,6-dihydroxy benzamid 
• 124479-80-7 2‐(methoxycarbonyl)‐1,3‐phenylene diacetate 
• 95449-97-1 3-acetyl-2,6-dihydroxy-benzoic acid methyl ester 
• 60237-95-8 2,6-dihydroxy-benzoic acid dimethylamide 
• 52234-79-4 2,6-dihydroxybenzoic acid N-methylamide 
• 116865-53-3 2,6-bis-(tetra-O-acetyl-β-D-glucopyranosyloxy)-benzoic acid methyl ester 
• 22833-69-8 methyl 6-methoxysalicylate 
• 154549-37-8 methyl 2,6-diisopropoxybenzoate 
• 6052-93-3 1,3,8-trihydroxyxanthone 
• 74292-71-0 2-Ethoxy-6-hydroxy-benzoic acid methyl ester 
• 130442-13-6 2-(methoxycarbonyl)-3-(tetradecyloxy)phenol 
• 131326-34-6 2,6-Bis-[6-(tert-butyl-dimethyl-silanyloxy)-hexyloxy]-benzoic acid methyl ester 
• 131326-27-7 2,6-Bis-[3-(2-benzyloxy-ethoxy)-propoxy]-benzoic acid methyl ester 

Relevant articles and documents

Anti-inflammatory glycosides from the roots of Paeonia intermedia C. A. Meyer

Three new phenolic glycosides, intermedia A–C (1–3), one new acyclic alcohol glycoside, intermedia D (4), together with 3 known glycosides (5–7), were isolated from the dried roots of Paeonia intermedia C. A. Meyer. Their structures were established by means of extensive spectroscopic analysis (HRESIMS, NMR). Compound 1 have a rare benzo[1,5]dioxepine skeleton. The bioassay results showed that compound 3 exhibited inhibitory activity against proinflammatory cytokines nitric oxide (NO) secretion in LPS-activated RAW264.7 cells with an IC50 value of 85.76 ± 1.36 μM.

Convergent Protein Phosphatase Inhibitor Design for PTP1B and TCPTP: Exchangeable Vanadium Coordination Complexes on Graphene Quantum Dots

Development of potent and specific inhibitors of protein tyrosine phosphatase 1B (PTP1B) with desired drug-like properties is still a challenge. Based on the crystal structures of PTP1B transition state analog consisting of a vanadate peptide, a novel approach is proposed to design PTP1B inhibitors, in which the tyrosyl vanadate ester of a PTP1B peptide mimic (PL1) is stably integrated on the membrane permeable graphene quantum dots (GQDs). The vanadate complexes (GQD-PL1-VV) prepared exhibit high potency (Ki?= 6?± 1?× 10?9 m) and selectivity (selectivity index SI >200?for PTP1B versus the T-cell protein tyrosine phosphatase, TCPTP) in solution and in HepG2 cells. Oral administration of GQD-PL1-VV in db/db model mice shows selective PTP1B inhibition in liver and fat tissues and exhibits improved anti-diabetic activity compared to bis(maltolato)oxovanadium(IV). Moreover, exchange of PL1 to a TCPTP-specific ligand (PL2) results in potent TCPTP inhibition (Ki?= 59?± 12?× 10?9 m) as expected with SI ≈23 versus PTP1B. Overall, the present results provide a paradigm shift and a general design of phosphatase inhibitors consisting of GQDs, a complexing targeting ligand and vanadium (V) for selective regulation of PTP1B both in vitro and vivo.

Pyrimidine salicylic acid derivative as well as preparation method and application thereof

The invention provides a pyrimidine salicylic acid derivative as well as a preparation method and application thereof. The chemical structural formula of the pyrimidine salicylic acid derivative is represented by a formula (I) (shown in the description). The preparation method comprises the step of reacting by virtue of acid of bispyribac-sodium and trifluoroethanol or 4-butenol in an organic solvent in the presence of triethylamine and 1-hydroxybenzotriazole, so as to obtain the compound of the formula (I). The preparation method is simple in operation and relatively high in yield, the prepared pyrimidine salicylic acid derivative is low in dose and high in activity, has herbicidal activities to agricultural weeds such as dicotyledon weeds and monocotyledon weeds at 15g/hm, particularly has relatively prevention effects to the after-treatment of seedlings of goosefoots and crab grass and can be taken as a candidate compound of herbicides, a new choice is provided for the new species of the herbicides, and the pyrimidine salicylic acid derivative has potential industrial application prospects.